HomeCompareARNI vs MO

ARNI vs MO: Dividend Comparison 2026

ARNI yields 1000000.00% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARNI wins by $4.7683925249533696e+36M in total portfolio value
10 years
ARNI
ARNI
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full ARNI calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — ARNI vs MO

📍 ARNI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARNIMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARNI + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARNI pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARNI
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, ARNI beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARNI + MO for your $10,000?

ARNI: 50%MO: 50%
100% MO50/50100% ARNI
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ARNI
No analyst data
Altman Z
-76.9
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARNI buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARNIMO
Forward yield1000000.00%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$4.7683925249533696e+36M$77.7K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$28,968.54
Total dividends collected$4.7683311610149396e+36M$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ARNI vs MO ($10,000, DRIP)

YearARNI PortfolioARNI Income/yrMO PortfolioMO Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,558$768.31+$100.00MARNI
2$934,786,450,701$934,679,439,252.34$11,352$1,015.87+$934786.44MARNI
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,482$1,367.86+$8165787108.57MARNI
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$14,103$1,883.39+$66665884190957.63MARNI
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$16,472$2,664.91+$508662171058048128.00MARNI
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$20,024$3,897.79+$3.62723524842849e+21MARNI
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$25,537$5,933.74+$2.417368115915061e+25MARNI
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$34,478$9,476.77+$1.5056740286145463e+29MARNI
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$49,776$16,022.63+$8.764771002818475e+32MARNI
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$77,699$28,968.54+$4.7683925249533696e+36MARNI

ARNI vs MO: Complete Analysis 2026

ARNIStock

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.

Full ARNI Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ARNI vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARNI vs SCHDARNI vs JEPIARNI vs OARNI vs KOARNI vs MAINARNI vs PMARNI vs BTIARNI vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.